Skip to main content Back to Top
Advertisement

11/15/2019

Mepivacaine Injection

Products Affected - Description

    • Carbocaine injection, Pfizer, 1%, 30 mL preservative-free vial, NDC 00409-1036-30
    • Carbocaine injection, Pfizer, 1%, 50 mL multiple dose vial, NDC 00409-1038-50
    • Carbocaine injection, Pfizer, 1.5%, 30 mL preservative-free vial, NDC 00409-1041-30
    • Carbocaine injection, Pfizer, 2%, 20 mL preservative-free vial, NDC 00409-1067-20
    • Carbocaine injection, Pfizer, 2%, 50 mL multiple dose vial, NDC 00409-2047-50
    • Polocaine-MPF injection, Fresenius Kabi, 1.5%, 30 mL preservative-free vial, NDC 63323-0293-37

Reason for the Shortage

    • Fresenius Kabi has Polocaine available.
    • Pfizer states the reason for the shortage is manufacturing delays.

Available Products

    • Polocaine injection, Fresenius Kabi, 1%, 50 mL multiple dose vial, NDC 63323-0283-57
    • Polocaine injection, Fresenius Kabi, 2%, 50 mL multiple dose vial, NDC 63323-0296-57
    • Polocaine-MPF injection, Fresenius Kabi, 1%, 30 mL preservative-free vial, NDC 63323-0260-37
    • Polocaine-MPF injection, Fresenius Kabi, 2%, 20 mL preservative-free vial, NDC 63323-0294-27

Estimated Resupply Dates

    • Fresenius Kabi has 1.5% Polocaine 30 mL preservative-free vials on back order and the company estimates a release date of early- to mid-December 2019.
    • Pfizer has 2% Carbocaine 20 mL preservative-free vials, 2% Carbocaine 50 mL multiple-dose vials, 1% Carbocaine 30 mL preservative-free vials, and 1.5% Carbocaine 30 mL preservative-free vials on back order and the company estimates a release date of March 2020. The 1% Carbocaine 50 mL multiple-dose vials are on back order and the company estimates a release date of December 2019.

Updated

Updated November 15, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 9, 2017 by Elyse MacDonald, PharmD, MS, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins